-
The Effect of Albumin Replacement on Vasopressor Duration in Septic Shock in Patients With Hypoalbuminemia Ann. Pharmacother. (IF 2.9) Pub Date : 2024-03-15 Jacob P. Counts, Joshua Arnold, Sara Atyia, Stella Ogake, Rachel M. Smith, Bruce Doepker
Background:The use of albumin resuscitation in septic shock is only recommended in patients who have received large volumes of crystalloid resuscitation regardless of serum albumin concentration. The role of albumin is still largely debated and evidence to support its use still lacking.Objective:The objective of this study was to evaluate whether albumin replacement increases the number of vasopressor-free
-
Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System Ann. Pharmacother. (IF 2.9) Pub Date : 2024-02-26 Yi Zhao, Yuzhou Zhang, Lin Yang, Kanghuai Zhang, Sha Li
Background:Selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed agents to treat depression. Considering the growth in antidepressant prescription rates, SSRI-induced adverse events (AEs) need to be comprehensively clarified.Objective:This study was to investigate safety profiles and potential AEs associated with SSRIs using the Food and Drug Administration Adverse Event
-
Incidence of Hypertriglyceridemia in Patients on Propofol, Clevidipine, or Both Ann. Pharmacother. (IF 2.9) Pub Date : 2024-02-26 Christopher B. Johns, Travis W. Fleming, Skyler R. Brown, Rebekah B. Black, A. Shaun Rowe
Background:Propofol and clevidipine (PC) are commonly used in the treatment of critically ill patients. While both medications are lipid emulsions, there is limited evidence concerning the incidence of hypertriglyceridemia (HTG) when these agents are used individually or concurrently.Objective:The objective of this study is to determine the effects of propofol, clevidipine, or concurrent PC on triglycerides
-
Sugammadex Use Outside of the Postoperative Setting Ann. Pharmacother. (IF 2.9) Pub Date : 2024-02-23 Hayley T. Gartner, Megan A. Rech
Background:Sugammadex rapidly reverses the nondepolarizing neuromuscular blocking agents (NMBAs) rocuronium and vecuronium. The role of sugammadex is not well-defined outside of the postoperative setting.Objective:This study aims to describe sugammadex use outside the postoperative setting for the reversal of nondepolarizing NMBAs.Methods:This was a single-center, retrospective cohort study conducted
-
Eye Drop Quality Issues: Can the FDA See This One Through? Ann. Pharmacother. (IF 2.9) Pub Date : 2024-02-21 Lyla R. White, C. Michael White
The Food and Drug Administration (FDA) has long suffered from a lack of resources limiting their inspection capacity. They have fallen behind on proactive surveillance inspections of foreign manufacturing sites, relying instead on for-cause inspections after a problem has been discovered. Over-the-counter (OTC) products are especially vulnerable because the FDA considers them lower priority. This issue
-
Preoperative Amiodarone and Primary Graft Dysfunction in Heart Transplantation Ann. Pharmacother. (IF 2.9) Pub Date : 2024-02-16 Abigail Servais, Scott Lundgren, Stephanie Bowman, Douglas Stoller, Adam Burdorf, Marshall Hyden, Brian Lowes, Ronald Zolty, Don Klepser, Heidi Brink
Background:Preoperative amiodarone effects on postorthotopic heart transplant (OHT) outcomes remain controversial.Objective:The purpose of this study was to determine the effect of cumulative pre-OHT amiodarone exposure on severe primary graft dysfunction (PGD).Methods:We retrospectively reviewed adult OHT recipients between August 2012 and June 2018. Primary outcome was severe PGD in patients receiving
-
Evaluation of Short Versus Long Courses of Antibiotics in Critically Ill Patients With Gram-Negative Bloodstream Infections Ann. Pharmacother. (IF 2.9) Pub Date : 2024-02-13 Daniel T. Anderson, Divisha Sharma, Aaron M. Chase, Zoheb Irshad Sulaiman, August H. Anderson, Ashley L. Huggett, Joshua Eudy
Background:Short courses of antibiotics (7-10 days) are effective for uncomplicated gram-negative bloodstream infections (GN-BSI). However, prior studies have been limited to small cohorts of critically ill patients.Objective:The objective of this study was to evaluate the safety and efficacy of short courses of therapy compared with longer courses in patients admitted to the intensive care unit (ICU)
-
Exploring Safety in Gender-Affirming Hormonal Treatments: An Observational Study on Adverse Drug Events Using the Food and Drug Administration Adverse Event Reporting System Database Ann. Pharmacother. (IF 2.9) Pub Date : 2024-02-13 Ainhoa Gomez-Lumbreras, Lorenzo Villa-Zapata
Background:People with gender dysphoria are treated with hormone therapy for gender reassignment. The indication of this therapy was initially for the opposite sex, and information on potential adverse drug reaction (ADR) is lacking.Objective:To describe ADR associated with gender transition medication in transgender individuals reported to the US Food and Drug Administration Adverse Event Reporting
-
Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer Ann. Pharmacother. (IF 2.9) Pub Date : 2024-02-12 Brian Lam, Jo E. Rodgers, Benyam Muluneh, Darrian Proco, Young E. Whang, Katherine P. Morgan
Background:Abiraterone acetate (AA) is used in treatment of patients with metastatic prostate cancer. Despite the survival advantage, AA is associated with hypertension due to mineralocorticoid excess syndrome.Objective:We conducted a single-center retrospective analysis to evaluate the real-world incidence and severity of AA-induced hypertension.Methods:Electronic health records were used to collect
-
Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis Ann. Pharmacother. (IF 2.9) Pub Date : 2024-02-12 David Choi, Hilary Sheridan, Shubha Bhat
Objective:To review the pharmacologic and clinical profile of mirikizumab in the treatment of moderate to severe ulcerative colitis (UC).Data sources:A PubMed search was performed from inception to December 2023 using keywords mirikizumab, interleukin-23 inhibitor, and UC. Information was also obtained from package inserts as well as published abstracts.Study selection and data extraction:Phase 3 studies
-
The Impact of Glycemic Control on Sodium-Glucose Co-Transporter 2 Inhibitor–Associated Genitourinary Infections Ann. Pharmacother. (IF 2.9) Pub Date : 2024-02-07 Anthony Gerber, Victoria Rupp, Natalia Ryabenkova, Nataliya Mikhelzon
Background:Patients with type 2 diabetes (T2D) are at an increased risk of genital urinary (GU) infections, with the risk increasing with higher A1Cs. Given the broad adoption of sodium-glucose co-transporter 2 inhibitors (SGLT2is) in patients with T2D, both providers and patients need to be aware of common adverse effects associated with these medications, specifically GU infections. However trials
-
Clinical Response to Third-Line Angiotensin-II vs Epinephrine in Septic Shock: A Propensity-Matched Cohort Study Ann. Pharmacother. (IF 2.9) Pub Date : 2024-02-02 Caitlyn R. Blankenship, Kevin D. Betthauser, Laura N. Hencken, Julie A. Maamari, Jenna Goetz, Bria D. Giacomino, Gabrielle A. Gibson
Background:The appropriate third-line vasopressor in septic shock patients receiving norepinephrine and vasopressin is unknown. Angiotensin-II (AT-II) offers a unique mechanism of action to traditionally used vasopressors in septic shock.Objective:The objective of this study was to compare the clinical efficacy and safety of third-line AT-II to epinephrine in patients with septic shock.Methods:A single-center
-
Evaluation of a Pharmacist-Led Implementation of Standardized Medication Administration Times for Inpatients Receiving Hemodialysis Ann. Pharmacother. (IF 2.9) Pub Date : 2024-01-31 Abbie L. Blunier, Megan R. Cheatham, Karishma S. Deodhar, Christopher A. Geik, Todd A. Walroth, Jessica A. Whitten, Christie M. Davis
Background:Missed medication doses are a common and often preventable medication-related error that have been associated with an increased length of stay and mortality. Hemodialysis is a common, relatively predictable reason that patients are unavailable, resulting in missed doses.Objective:To evaluate the implications of a pharmacist-led intervention to standardize the medication administration times
-
Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19 Ann. Pharmacother. (IF 2.9) Pub Date : 2024-01-30 Hannah B. Knox, Lisa A. Dykes, Lancer A. Scott, Bradley C. Presley, Lara C. Lambert
Background:The COVID-19 pandemic has led to a rapid, exponential increase in hospitalizations and morbidity/mortality. In November 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) permitting administration of the first monoclonal antibodies (mAb) for outpatient treatment of COVID-19. Early data showed a reduction in COVID-19-related hospitalizations with few adverse
-
Epidemiology of Vancomycin in Combination With Piperacillin/Tazobactam-Associated Acute Kidney Injury in Children: A Systematic Review and Meta-analysis Ann. Pharmacother. (IF 2.9) Pub Date : 2024-01-27 Miao Zhang, Liang Huang, Yu Zhu, Linan Zeng, Zhi-Jun Jia, Guo Cheng, Hailong Li, Lingli Zhang
Background:Several studies have shown that vancomycin combined with piperacillin/tazobactam (VPT) increased the risk of acute kidney injury (AKI) compared with other antibiotics in children. However, the epidemiology of VPT-associated AKI in children is unknown.Objective:To evaluate the incidence and risk factors of VPT-associated AKI in children.Data sources:Literature databases of PubMed, Embase
-
Documentation of the Patient Characteristics Morbid Obesity and Bariatric Surgery in the Hospital Information System and the Influence on the Number of Medication-Related Problems Ann. Pharmacother. (IF 2.9) Pub Date : 2024-01-25 Jurjen S. Kingma, Iris A. M. Brenkman, Marcel P. H. van den Broek, Patricia M. L.A. van den Bemt, Karin Janssen, Catherijne A. J. Knibbe, Desirée M. T. Burgers
Background:As a result of pharmacokinetic changes, individuals with morbid obesity and/or with bariatric surgery may require dose adjustments, additional monitoring or medication should be avoided. Clinical decision support (CDS) may provide automated alerts enabling correct prescribing but requires documentation of these patient characteristics in the Hospital Information System (HIS) to prevent medication-related
-
Impact of a Divided Phenobarbital Load and Taper Compared With Lorazepam Symptom Triggered Therapy in Hospitalized Patients Ann. Pharmacother. (IF 2.9) Pub Date : 2024-01-23 Alyson M. Esteves, Matthew C. Buchfellner, Brooke M. Holmes, Joseph A. Berndsen, Matthew A. Roginski
Background:Benzodiazepines are the preferred treatment for alcohol withdrawal. Phenobarbital is an alternative in the setting of prescriber expertise or benzodiazepine contraindication.Objective:To evaluate the efficacy and safety of a phenobarbital dosing strategy aimed at treating a spectrum of alcohol withdrawal symptoms across various patient populations.Methods:Retrospective review of patients
-
Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis Ann. Pharmacother. (IF 2.9) Pub Date : 2024-01-23 David Choi, Michelle Becker, Marina Ivanov, Shubha Bhat
Objective:To review the pharmacologic and clinical profile of etrasimod in the treatment of ulcerative colitis (UC).Data sources:A PubMed search was conducted from inception to November 2023 using the keywords etrasimod, ulcerative colitis, and sphingosine-1-phosphate receptor modulator. Information was also obtained from published abstracts and package insert.Study selection and data extraction:Phase
-
Phenobarbital Versus Benzodiazepines for the Treatment of Severe Alcohol Withdrawal Ann. Pharmacother. (IF 2.9) Pub Date : 2024-01-22 Katherine M. Kessel, Logan M. Olson, Derek A. Kruse, Elizabeth R. Lyden, Kelsey E. Whiston, Mindy M. Blodgett, Alena A. Balasanova
Background:Phenobarbital may offer advantages over benzodiazepines for severe alcohol withdrawal syndrome (SAWS), but its impact on clinical outcomes has not been fully elucidated.Objective:The purpose of this study was to determine the clinical impact of phenobarbital versus benzodiazepines for SAWS.Methods:This retrospective cohort study compared phenobarbital to benzodiazepines for the management
-
Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies Ann. Pharmacother. (IF 2.9) Pub Date : 2024-01-18 Madeline D. Schultze, David J. Reeves
Objective:The objective was to evaluate the efficacy/safety of pirtobrutinib in the treatment of B-cell malignancies and distinguish it from other available Bruton’s tyrosine kinase (BTK) inhibitors.Data sources:A literature search of PubMed (January 2021 through November 2023) and Clinicaltrials.gov was conducted using terms pirtobrutinib, Jaypirca, and LOXO 305. Licensing trials of available BTK
-
Efficacy of Fluvoxamine in Outpatients With COVID-19: Understanding Conflicting Conclusions From 2 Recent Meta-Analyses of the Same Clinical Trials. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-11-28 Marina Sánchez-Rico,Katayoun Rezaei,Eric J Lenze,Frédéric Limosin,Nicolas Hoertel
-
Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-11-28 Allissa Long,Marissa Salvo
OBJECTIVE To describe the pharmacology, clinical efficacy, and safety evidence of sotagliflozin, the first approved dual inhibitor of sodium-glucose cotransporter (SGLT) 1 and SGLT2, in heart failure (HF) management. DATA SOURCES A literature search of studies published between January 2012 and September 2023 were identified using PubMed, MEDLINE, and clinicaltrials.gov with search terms of "sotagliflozin
-
Assessing the Clinical, Economic, and Health Resource Utilization Impacts of Prefilled Syringes Versus Conventional Medication Administration Methods: Results From a Systematic Literature Review. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-11-28 Dan Benhamou,Mia Weiss,Matthias Borms,Julia Lucaci,Haymen Girgis,Cecile Frolet,Wesley T Baisley,Gio Shoushi,Kristen A Cribbs,Manuel Wenk
OBJECTIVE The objective of this systematic review was to assess the clinical, economic, and health resource utilization outcomes associated with the use of prefilled syringes in medication administration compared with traditional preparation methods. DATA SOURCES We conducted a systematic literature review to evaluate outcomes such as medication errors, wastage, time savings, and contamination in prefilled
-
A Complement to Traditional Treatments for Antibody-Mediated Rejection? Use of Eculizumab in Lung Transplantation: A Review and Early Center Experience. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-11-23 Hanna L Kleiboeker,Alyson Prom,Krista Paplaczyk,Catherine N Myers
OBJECTIVE To review the efficacy and safety of eculizumab for prevention and treatment of antibody-mediated rejection (AMR) in lung transplant recipients (LTRs). DATA SOURCES A literature search of PubMed and the Cochrane Controlled Trials Register (2007 to mid-October 2023) was performed using the following search terms: eculizumab, complement inhibitor, solid organ transplant, lung transplant, and
-
Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-11-23 Courtney S Pilkerton,Megan Adelman,Emily Crocetti,Jun Xiang,Victoria Strick,Charles D Ponte,Shaylee Peckens,Benjamin P Jackson,Kylen Whipp,Amie M Ashcraft
BACKGROUND Direct-acting oral anticoagulants (DOACs) have become the preferred drugs for managing venous thromboembolism (VTE). Despite their advantages over vitamin K antagonists such as warfarin, their use in obese patients remains controversial with many providers reluctant to switch patients managed on warfarin. Outcome research that opts to increase provider confidence when prescribing DOACs for
-
Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-11-17 John A Dougherty,Kristiann M Dougherty
OBJECTIVE To review efficacy and safety data of valoctocogene roxaparvovec (Roctavian) and etranacogene dezaparavovec (Hemgenix), novel gene therapies for the treatment of the life-threatening bleeding disorders hemophilia A and B, respectively. DATA SOURCES A PubMed/Google Scholar search from inception through August 11, 2023 was conducted using the following keywords: gene therapy, hemophilia A,
-
Combination of Rivaroxaban and Amiodarone Increases Bleeding in Patients With Atrial Fibrillation. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-11-13 Zi Wang,Xiaoyu Li,Ye Zou,Xiaoye Li,Qianzhou Lv
BACKGROUND Rivaroxaban and amiodarone are commonly used for treating patients with atrial fibrillation. Drug-drug interactions between rivaroxaban and amiodarone may increase exposure to rivaroxaban. However, the clinical relevance of this drug-drug interaction is still not clear. OBJECTIVE The aim was to investigate the risk of bleeding in patients receiving a combination of rivaroxaban and amiodarone
-
Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-11-12 Alison Rydell,Corianne Thackrey,Maryam Molki,Brandon P Mullins
BACKGROUND Patiromer and sodium zirconium cyclosilicate (SZC) are 2 oral potassium binders approved for chronic hyperkalemia. It is unknown if one is more effective at reducing serum potassium than the other in acute hyperkalemia. OBJECTIVE The objective of this study was to determine if there was a difference between patiromer and SZC in the reduction of serum potassium in patients with acute hyperkalemia
-
Risk of Tendon Injury in Patients Treated With Fluoroquinolone (FQ) Versus Non-Fluoroquinolone Antibiotics for Community-Acquired Pneumonia (CAP). Ann. Pharmacother. (IF 2.9) Pub Date : 2023-11-09 Virginia H Fleming,Jianing Xu,Xianyan Chen,Daniel Hall,Robin L Southwood
BACKGROUND Fluoroquinolones (FQs) are associated with increased risk of tendon injury but comparative risk versus other antibiotic options for the same indication has yet to be evaluated. OBJECTIVE Describe the incidence (relative risk) of any tendon injury in patients receiving FQ compared with other (non-FQs) antibiotics for treatment of community-acquired pneumonia (CAP). METHODS A retrospective
-
Fanconi Syndrome in Patients With Human Immunodeficiency Virus Treated With Tenofovir-Based Antiretroviral Therapy: A Systematic Literature Review. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-11-06 Mrinmayee Joshi,Brendan Clark,Todd A Lee
OBJECTIVE Several cases of Fanconi syndrome (FS), a severe form of nephrotoxicity, have been reported in patients with HIV on tenofovir-containing antiretroviral therapy. A systematic review of the published literature on tenofovir-related FS in patients with HIV was conducted. DATA SOURCES PubMed and Embase were queried to identify articles in English published between January 2005 and June 2023,
-
The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-10-30 Dana Kaminski,Justin P Reinert
OBJECTIVE The objective of this systematic review is to determine the tolerability and safety of psilocybin in a variety of psychiatric and substance-dependence conditions. DATA SOURCES A systematic review was conducted using Embase, PubMed, Cochrane Central, and Web of Science through September 2023 using the following terminology: "psilocybin" AND "mental-disease" OR "substance-dependence" AND "disease-therapy
-
Real-World Experience With CMV inSIGHT T Cell Immunity Testing in High-Risk Kidney and Pancreas Transplant Recipients. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-10-28 Jillian L Descourouez,Jeannina A Smith,Christopher M Saddler,Didier A Mandelbrot,Jon S Odorico,Margaret R Jorgenson
BACKGROUND Cytomegalovirus (CMV)-specific cell-mediated immunity is important for control of CMV after transplant. Assays exist to measure this, but their place in therapy is unclear, particularly in CMV high-risk recipients, without pretransplant exposure. OBJECTIVE The objective of this study was to evaluate predictive potential of a positive assay to determine freedom from DNAemia and describe subsequent
-
Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-10-27 Elizabeth Hageman,Mia E Lussier
OBJECTIVE This article aims to discuss elacestrant, an oral selective estrogen receptor downregulator approved by the Food and Drug Administration (FDA) in January 2023 for the treatment of hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. DATA SOURCES PubMed, Embase, Medline, Clinicaltrials.gov, and the National Comprehensive Cancer Network
-
Evaluation of Newly Integrated Bivalirudin Titration Protocol in Patients With Mechanical Circulatory Support. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-10-27 Madeline Mitchell,Danine Sullinger,Duke Dyer,Gavin Hickey,David Kaczorowski,Joni Minor,Holt Murray,Raj Ramanan,Zachary Rhinehart,Mark Schmidhofer,Ryan M Rivosecchi
BACKGROUND Patients with cardiogenic shock or end-stage heart failure can be maintained on mechanical circulatory support (MCS) devices. Once a patient undergoes placement of a device, obtaining and maintaining therapeutic anticoagulation is vital. Guidelines recommend the use of institutional protocols to assist in dosing and titration of anticoagulants. OBJECTIVE The purpose of this study was to
-
LCP-Tacrolimus Requires a Similar Empiric Dose Adjustment to Immediate-Release Tacrolimus When Given Concomitantly With Letermovir for Cytomegalovirus Primary Prophylaxis. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-10-27 Jillian L Descourouez,Didier A Mandelbrot,Jon Odorico,Margaret R Jorgenson
-
Ertapenem Versus Meropenem for the Treatment of Extended Spectrum Beta-Lactamase-Producing Enterobacterales Bacteremia in Critically Ill Patients. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-10-26 Sydney VanDorf,Prakash Shah,Christine N Yost
BACKGROUND The preferred carbapenem for treatment of infections caused by extended spectrum beta-lactamase-producing Enterobacterales (ESBL-E) in critically ill patients is debated. OBJECTIVE The purpose of this study was to evaluate the difference in clinical failure between ertapenem and meropenem for treatment of ESBL-E bacteremia in critically ill patients. Of concern is ertapenem use in hypoalbuminemia
-
Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-10-26 Kristen Wilhite,Jennifer Meyer Reid,Matthew Lane
BACKGROUND Incretin therapies, comprised of the dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have been increasingly utilized for the treatment of type 2 diabetes (T2DM). Previous studies have conflicting results regarding risk of pancreatitis associated with these agents-some suggest an increased risk and others find no correlation. Adverse event
-
Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-10-26 Michael Cristian Garcia,Kai La Tsang,Simran Lohit,Jiawen Deng,Tyler Schneider,Jessyca Matos Silva,Lawrence Mbuagbaw,Anne Holbrook
OBJECTIVES We aimed to evaluate the high-quality literature on the frequency and nature of major adverse cardiac events (MACE) associated with either hydroxychloroquine (HCQ) or chloroquine (CQ). DATA SOURCES We searched Medline, Embase, International Pharmaceutical Abstracts, and Cochrane Central from 1996 onward using search strategies created in collaboration with medical science librarians. STUDY
-
Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-10-24 Kylie N Barnes,Claire M Vogl,Leigh Anne Nelson
OBJECTIVE The objective of this study was to review the characteristics, efficacy, and safety of zuranolone in the management of postpartum depression (PPD). DATA SOURCES Literature was identified using PubMed (1966-August 2023) and EMBASE (1973-August 2023) and clinicaltrials.gov. Search terms included zuranolone, SAGE-217, and PPD with further limitation of those published in English. STUDY SELECTION
-
Incorporation of Innovative Strategies for Patient Education in Pharmacist-Led Transition of Care Initiatives. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-10-10 Maria Miller Thurston,Lori H Dupree,Angela Shogbon Nwaesei,Lydia C Newsom
As patients transition between health care settings, they are at an increased risk of adverse events and medication errors as a result of medication changes and miscommunication. Pharmacists have traditionally provided transitions of care (TOC) services, including patient education, in a face-to-face manner with the goal of reducing medication errors and enhancing patient safety and understanding.
-
Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-10-10 Benjamin August,Andrew Matlob,Pramodini B Kale-Pradhan
OBJECTIVE To review the pharmacology, efficacy, and safety of intravenous sulbactam-durlobactam (SUL-DUR) in the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections. DATA SOURCES PubMed databases and ClinicalTrials.gov were searched using the following terms: Sulbactam Durlobactam, ETX2514, Xacduro, Sulbactam-ETX2514, ETX2514SUL. STUDY SELECTION AND DATA EXTRACTION Articles
-
The Impact of Ketamine for Treatment of Post-Traumatic Stress Disorder: A Systematic Review With Meta-Analyses. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-30 Dakota J Sicignano,Ryan Kurschner,Nissen Weisman,Ava Sedensky,Adrian V Hernandez,C Michael White
BACKGROUND Ketamine has been used in anesthesia, pain management, and major depressive disorder. It has recently been studied in patients with post-traumatic stress disorder (PTSD). OBJECTIVE To determine the impact of ketamine on PTSD symptomatology and depression scores. METHODS We conducted a literature search of Medline 1960 to May 20, 2023, and found 6 randomized controlled trials that met our
-
Pharmacokinetics of Levetiracetam Seizure Prophylaxis in Severe Traumatic Brain Injury. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-30 Sarah Schuman Harlan,Carolyn D Philpott,Shaun P Keegan,Molly E Droege,Aniruddha S Karve,Brandon Foreman,Devin Wakefield,Eric W Mueller,Kiranpal Sangha,Laura B Ngwenya,Joshua D Courter,Pankaj Desai,Christopher Droege
BACKGROUND Drug pharmacokinetics (PK) are altered in neurocritically ill patients, and optimal levetiracetam dosing for seizure prophylaxis is unknown. OBJECTIVE This study evaluates levetiracetam PK in critically ill patients with severe traumatic brain injury (sTBI) receiving intravenous levetiracetam 1000 mg every 8 (LEV8) to 12 (LEV12) hours for seizure prophylaxis. METHODS This prospective, open-label
-
Trimethoprim/Sulfamethoxazole vs Minocycline for the Treatment of Nonurinary Monomicrobial Stenotrophomonas maltophilia Infections in Hospitalized Patients. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-30 Emma C Hevia,Leslie Wooten,Amy L Carr
BACKGROUND Stenotrophomonas maltophilia is an opportunistic, gram-negative bacillus with few therapeutic options due to a high level of intrinsic resistance. Trimethoprim/sulfamethoxazole (SXT) is recommended as the first-line treatment; however, minocycline (MIN) has been shown to have similar clinical outcomes in treating S. maltophilia and addresses concern for increasing resistance to SXT. OBJECTIVE
-
Treatment Outcomes for Carbapenem-Resistant and Cephalosporin-Susceptible Pseudomonas aeruginosa Pneumonia. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-26 Tsz Hin Ng,Jing J Zhao,Ryan Gumbleton,Shannon Olson,Stephanie Smith,Marco R Scipione
BACKGROUND Carbapenem-resistant (Car-R) Pseudomonas aeruginosa is an urgent threat. These isolates may remain susceptible to traditional noncarbapenem antipseudomonal β-lactams, but it is unclear if carbapenem resistance impacts the effectiveness of these agents. OBJECTIVE The purpose of this study was to compare clinical outcomes in Car-R and cephalosporin-susceptible (Ceph-S) P. aeruginosa pneumonia
-
Comparison of the Effectiveness and Safety of Clozapine Between Once-Daily and Divided Dosing Regimen in Patients With Treatment-Resistant Schizophrenia. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-24 Thanompong Sathienluckana,Thaksin Jansing,Supakan Srisuriyakamon,Aunchalee Thonkhunthod,Parsiri Sangsuwanto,Pholphat Losatiankij,Suttha Supanya
BACKGROUND Clozapine is the most effective antipsychotic with respect to the incidence of discontinuation and is indicated for treatment-resistant schizophrenia. Although the recommendation for clozapine administration is divided dosing, once-daily dosing of clozapine is commonly prescribed in many countries. However, there is currently no clinical data comparing all-cause discontinuation between the
-
Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-24 Amy Duong,Samantha Heacock,Sarah Amering,Lillian Brennan,Jineane Venci,Nicole M Acquisto
BACKGROUND Limited real-world data on the benefits and risks associated with 3 and 4.5 mg doses of dulaglutide currently exists, making it difficult to determine the impact of dose titration for patients currently managed with dulaglutide 1.5 mg weekly. OBJECTIVE To determine the impact of dulaglutide 3 and 4.5 mg doses on weight and hemoglobin A1c (HbA1c) in patients with type 2 diabetes mellitus
-
Keeping It "Current": A Review of Treatment Options for the Management of Supraventricular Tachycardia. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-24 Patrick Tednes,Samantha Marquardt,Shannon Kuhrau,Kristin Heagler,Megan Rech
OBJECTIVE To review treatment options and updates that exist for the management of paroxysmal supraventricular tachycardia (PSVT). DATA SOURCES A literature search of PubMed was performed including articles from 1974 to June 2023 using the terms: arrhythmias, adenosine, verapamil, diltiazem, esmolol, propranolol, metoprolol, beta-blockers, amiodarone, PSVT, synchronized cardioversion, methylxanthines
-
Off-Label Reduced Dose Apixaban in Older Adults With Atrial Fibrillation and Associated Outcomes. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-15 Ashley M Campbell,Elizabeth Pae,Eunice Lee,Timothy Jacisin,Alina Price,Jessica DeAngelo
BACKGROUND Apixaban is commonly used to prevent stroke in older adults with nonvalvular atrial fibrillation (AF). Although its package insert has specific dose reduction criteria, providers may dose reduce outside of these parameters based on clinical scenarios. OBJECTIVE The primary objective was to determine the incidence of apixaban off-label reduced dosing, while secondarily determining the safety
-
Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-14 Ada W Chiu,Nina Bredenkamp
OBJECTIVE To provide an overview of the guidelines on the management of immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), review the evidence for sparsentan, and discuss its place in therapy. DATA SOURCES A literature search was conducted using MEDLINE, EMBASE, and clinicaltrials.gov using the search terms "sparsentan" and "RE-021" up to the end of Jun 2023. STUDY SELECTION
-
CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-13 Yundi Zhang,Yue Du,Shuyu Ren,Yue Li,Xiaoming Zhang,Xiaohong Cao,Fengxi Liu,Huiying Zong,Yan Li
BACKGROUND The effect of drug-drug interaction (DDI) between tacrolimus and voriconazole on the pharmacokinetics of tacrolimus in different CYP3A5 genotypes has not been reported in previous studies. OBJECTIVE The objective of this study was to investigate whether CYP3A5 genotype could influence tacrolimus-voriconazole DDI in Chinese kidney transplant patients. METHODS All kidney transplant patients
-
Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-12 Natalie Mausey,Zachery Halford
OBJECTIVE To evaluate the safety and efficacy of the novel KRAS-targeting agents, sotorasib and adagrasib, in treating KRAS G12C-mutated non-small cell lung cancer (NSCLC). DATA SOURCES A comprehensive English-based literature search of PubMed and Clinicaltrials.gov between January 2000 and July 2023 was conducted using the terms sotorasib, Lumakras, AMG 510, adagrasib, Krazati, and MRTX849. STUDY
-
Evaluation of Basal Plus Versus Sliding Scale Insulin Therapy on Glucose Variability in Critically Ill Patients Without Preexisting Diabetes. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-12 Rachel E Webster,Julie J Belfer,Kyle J Schmidt
BACKGROUND There is limited evidence evaluating the impact of insulin treatment strategies on glucose variability in critically ill patients without preexisting diabetes. OBJECTIVE Compare basal plus insulin (BPI) and sliding scale insulin (SSI) impact on glycemic control outcomes in critically ill patients without preexisting diabetes experiencing hyperglycemia. METHODS This multicenter, retrospective
-
Intranasal Theophylline: Potential Treatment for Long COVID Olfactory Dysfunction? Ann. Pharmacother. (IF 2.9) Pub Date : 2023-09-07 Olga Hilas,Tina Caliendo
-
Invasive SCC and Tirbanibulin: Experience in Patient With Epidermodysplasia Verruciformis. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-08-31 Andrea Agostini,Nicole Macagno,Rebecca Senetta,Pietro Quaglino,Paolo Broganelli
-
Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis: A Drug Review. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-08-31 Cameron Lanier,Tyler C Melton
OBJECTIVE The objective of the study is to describe and analyze the pharmacodynamics and pharmacokinetics of oteseconazole as well as the clinical evidence supporting the efficacy of oteseconazole in treating recurrent vulvovaginal candidiasis (RVVC). DATA SOURCES A literature search was conducted using MEDLINE and EMBASE databases (2015-June 2023). Search terms included "oteseconazole" OR "VT-1161"
-
Authors Reply to Comment on Rotshild et al's "The Risk for Prostate Cancer With Calcium Channel Blockers". Ann. Pharmacother. (IF 2.9) Pub Date : 2023-08-23 Victoria Rotshild,Ilan Matok
-
Comment on Rotshild et al's "The Risk for Prostate Cancer With Calcium Channel Blockers". Ann. Pharmacother. (IF 2.9) Pub Date : 2023-08-23 Kuan-Fu Liao,Bing-Fang Hwang,Chiu-Shong Liu,Shih-Wei Lai
-
The Role of Dexmedetomidine in Paroxysmal Sympathetic Hyperactivity: A Systematic Review. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-08-22 Cole R Jerousek,Justin P Reinert
OBJECTIVE The objective was to evaluate the efficacy and safety of dexmedetomidine in the treatment and prophylaxis of paroxysmal sympathetic hyperactivity (PSH). DATA SOURCES A review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria and queried Embase, MEDLINE (PubMed), Cochrane CENTRAL, Web of Science, SciELO, Korean Journal
-
A Comparison of Injectable Diazepam and Lorazepam in the Goal-Directed Management of Severe Alcohol Withdrawal. Ann. Pharmacother. (IF 2.9) Pub Date : 2023-08-22 Kendall H Brickel,Emily K Hodge,Daria Zavgorodnyaya,John M Schroeder,Lawrence H Brown,Mitchell J Daley
BACKGROUND Benzodiazepines are the gold standard for treatment of alcohol withdrawal, yet the selection of a preferred benzodiazepine is limited due to a lack of comparative studies. OBJECTIVES The primary objective of this study was to compare the efficacy and safety of injectable lorazepam (LZP) and diazepam (DZP) in the treatment of severe alcohol withdrawal syndrome (AWS). METHODS Retrospective